Pharmaceuticals
-
Heart risk reducing for rheumatoid arthritis patients
Patients with rheumatoid arthritis have been enjoying a reduction in risk of cardiovascular disease since the turn of the century, a conference has heard. Read more
-
Test to enhance PARP treatment for prostate
British researchers have unveiled a blood test that can be used to identify men who are failing to respond to PARP inhibitor treatment for advanced prostate cancer. Read more
-
Gene test for oesophageal cancer drug
Scottish researchers have announced the discovery of a genetic test to identify patients who will benefit from a drug for oesophageal cancer. Read more
-
Drugs reducing RA demand for surgery, conference hears
The use of biological drugs can reduce the need for knee and hip replacements, a European conference has heard. Read more
-
Heart drug dosage should be adjusted by gender – study
Women should take lower dosages of cardiovascular drugs to help prevent adverse reactions, a new Spanish study has concluded. Read more
-
Pre-RA treatment backed at Euro-conference
Active treatment of patients thought to be developing rheumatoid arthritis successfully staves of disease development, a European conference has heard. Read more
-
Snake venom key to ‘safer antiplatelet drug’
A snake venom protein could be used to help develop a new, innovative class of antiplatelet drugs to prevent or reduce bleeding complications, according to a new study. Read more
-
Antibiotics guidance shake-up
A major shake-up of antibiotics classification has been announced in a bid to ensure careful use of the drugs. Read more
-
IL4 may be key to MI recovery for some
Interleukin-4 may help the recovery of some patients after myocardial infarction, a conference will hear today. Read more
-
Ulcer drug for depression?
A medicine prescribed for gastric ulcers may benefit people with depression via its effect on a protein called brain-derived neurotrophic factor, researchers reported last night. Read more
